

Subject index

Volume 38 (1998)

Acyclovir; Herpes simplex virus; Interferon; Ribonucleotide reductase; Synergy **38**, 107

Acyclovir; Interferon; Herpes simplex virus; Synergy **38**, 95

Adenovirus; N-chlorotaurine; Antiviral agent; Herpes simplex virus **38**, 25

Amantadine; Anti-influenza compounds; Rimantadine **38**, 213

Anti-influenza compounds; Amantadine; Rimantadine **38**, 213

Antisense; HIV-1; Combination therapy; Oligonucleotide; GEM 91[®]; Nucleoside analog **38**, 63

Antiviral activity; In vitro; In vivo; Poly(G)·poly(C); Polyribonucleotide duplexes; Structure; Template biosynthesis **38**, 131

Antiviral agent; N-chlorotaurine; Herpes simplex virus; Adenovirus **38**, 25

Antiviral; Foscarnet; Bioavailability; H₂-blocker; Ranitidine **38**, 209

Antiviral; Herpes; Immune cells; Virus; Topical; Foscarnet **38**, 43

Antiviral; RSV; Cotton rats; Pneumonia; Prophylaxis; Bronchiolitis **38**, 31

Aseptic meningitis; Enteroviruses; Summer flu; Viral syndrome; Coxsackieviruses **38**, 1

Bioavailability; Foscarnet; Antiviral; H₂-blocker; Ranitidine **38**, 209

Bronchiolitis; RSV; Cotton rats; Antiviral; Pneumonia; Prophylaxis **38**, 31

Cartesian coordinate analysis; CD4 + cell; HIV-1 RNA; Viral burden; Virulence; Virologic response modifiers; Pathogenesis; Clinical trials **38**, 181

CD4 + cell; Cartesian coordinate analysis; HIV-1 RNA; Viral burden; Virulence; Virologic response modifiers; Pathogenesis; Clinical trials **38**, 181

Clinical trials; Cartesian coordinate analysis; CD4 + cell; HIV-1 RNA; Viral burden; Virulence; Virologic response modifiers; Pathogenesis **38**, 181

Combination antivirals; Conference summary; Emerging viruses; Herpes viruses; Kaposi sarcoma; Hepatitis virus; Respiratory viruses **38**, 75

Combination therapy; HIV-1; Antisense; Oligonucleotide; GEM 91[®]; Nucleoside analog **38**, 63

Conference summary; Combination antivirals; Emerging viruses; Herpes viruses; Kaposi sarcoma; Hepatitis virus; Respiratory viruses **38**, 75

Cotton rats; RSV; Antiviral; Pneumonia; Prophylaxis; Bronchiolitis **38**, 31

Coxsackieviruses; Enteroviruses; Summer flu; Viral syndrome; Aseptic meningitis **38**, 1

Cytokine production; Interleukin 12; Influenza A virus infection; T helper type 1 **38**, 117

Delavirdine; HIV; Nevirapine; NNRTIs (non-nucleoside reverse transcriptase inhibitors); Reverse transcriptase; Triple-drug combinations **38**, 153

Distemper; Interferon α ; Measles; Plaque variants; Heat shock protein **38**, 195

Emerging viruses; Conference summary; Combination antivirals; Herpes viruses; Kaposi sarcoma; Hepatitis virus; Respiratory viruses **38**, 75

Enteroviruses; Summer flu; Viral syndrome; Coxsackieviruses; Aseptic meningitis **38**, 1

Fluoroalkylated oligomer; HIV-1; HSV-1; HSV-2; RSV; Viral adsorption inhibitor **38**, 141

Foscarnet; Bioavailability; Antiviral; H2-blocker; Rantidine **38**, 209

Foscarnet; Herpes; Immune cells; Virus; Topical; Antiviral **38**, 43

GEM 91®; HIV-1; Combination therapy; Antisense; Oligonucleotide; Nucleoside analog **38**, 63

H2-blocker; Foscarnet; Bioavailability; Antiviral; Rantidine **38**, 209

Heat shock protein; Interferon α ; Distemper; Measles; Plaque variants **38**, 195

Hepatitis virus; Conference summary; Combination antivirals; Emerging viruses; Herpes viruses; Kaposi sarcoma; Respiratory viruses **38**, 75

Herpes; Immune cells; Virus; Topical; Foscarnet; Antiviral **38**, 43

Herpes simplex virus; Acyclovir; Interferon; Ribonucleotide reductase; Synergy **38**, 107

Herpes simplex virus; Interferon; Acyclovir; Synergy **38**, 95

Herpes simplex virus; N-chlorotaurine; Antiviral agent; Adenovirus **38**, 25

Herpes viruses; Conference summary; Combination antivirals; Emerging viruses; Kaposi sarcoma; Hepatitis virus; Respiratory viruses **38**, 75

Heterologous G3-VP7; Homotypic single-VP7; Simian rotavirus SA11 **38**, 15

HIV-1; Combination therapy; Antisense; Oligonucleotide; GEM 91®; Nucleoside analog **38**, 63

HIV; Delavirdine; Nevirapine; NNRTIs (non-nucleoside reverse transcriptase inhibitors); Reverse transcriptase; Triple-drug combinations **38**, 153

HIV-1; Fluoroalkylated oligomer; HSV-1; HSV-2; RSV; Viral adsorption inhibitor **38**, 141

HIV-1 RNA; Cartesian coordinate analysis; CD4 + cell; Viral burden; Virulence; Virologic response modifiers; Pathogenesis; Clinical trials **38**, 181

Homotypic single-VP7; Heterologous G3-VP7; Simian rotavirus SA11 **38**, 15

HSV-2; Fluoroalkylated oligomer; HIV-1; HSV-1; RSV; Viral adsorption inhibitor **38**, 141

HSV-1; Fluoroalkylated oligomer; HIV-1; HSV-2; RSV; Viral adsorption inhibitor **38**, 141

Immune cells; Herpes; Virus; Topical; Foscarnet; Antiviral **38**, 43

Influenza A virus infection; Interleukin 12; T helper type 1; Cytokine production **38**, 117

Interferon α ; Distemper; Measles; Plaque variants; Heat shock protein **38**, 195

Interferon; Herpes simplex virus; Acyclovir; Ribonucleotide reductase; Synergy **38**, 107

Interferon; Herpes simplex virus; Acyclovir; Synergy **38**, 95

Interleukin 12; Influenza A virus infection; T helper type 1; Cytokine production **38**, 117

In vitro; Antiviral activity; In vivo; Poly(G)·poly(C); Polyribonucleotide duplexes; Structure; Template biosynthesis **38**, 131

In vivo; Antiviral activity; In vitro; Poly(G)·poly(C); Polyribonucleotide duplexes; Structure; Template biosynthesis **38**, 131

Kaposi sarcoma; Conference summary; Combination antivirals; Emerging viruses; Herpes viruses; Hepatitis virus; Respiratory viruses **38**, 75

Measles; Interferon α ; Distemper; Plaque variants; Heat shock protein **38**, 195

N-chlorotaurine; Antiviral agent; Herpes simplex virus; Adenovirus **38**, 25

Nevirapine; Delavirdine; HIV; NNRTIs (non-nucleoside reverse transcriptase inhibitors); Reverse transcriptase; Triple-drug combinations **38**, 153

NNRTIs (non-nucleoside reverse transcriptase inhibitors); Delavirdine; HIV; Nevirapine; Reverse transcriptase; Triple-drug combinations **38**, 153

Nucleoside analog; HIV-1; Combination therapy; Antisense; Oligonucleotide; GEM 91® **38**, 63

- Oligonucleotide;** HIV-1; Combination therapy; Antisense; GEM 91®; Nucleoside analog **38**, 63
- Pathogenesis;** Cartesian coordinate analysis; CD4+ cell; HIV-1 RNA; Viral burden; Virulence; Virologic response modifiers; Clinical trials **38**, 181
- Plaque variants;** Interferon α ; Distemper; Measles; Heat shock protein **38**, 195
- Pneumonia;** RSV; Cotton rats; Antiviral; Prophylaxis; Bronchiolitis **38**, 31
- Poly(G)·poly(C);** Antiviral activity; In vitro; In vivo; Polyribonucleotide duplexes; Structure; Template biosynthesis **38**, 131
- Polyribonucleotide duplexes;** Antiviral activity; In vitro; In vivo; Poly(G)·poly(C); Structure; Template biosynthesis **38**, 131
- Prophylaxis;** RSV; Cotton rats; Antiviral; Pneumonia; Bronchiolitis **38**, 31
- Ranitidine;** Foscarnet; Bioavailability; Antiviral; H2-blocker **38**, 209
- Respiratory viruses;** Conference summary; Combination antivirals; Emerging viruses; Herpes viruses; Kaposi sarcoma; Hepatitis virus **38**, 75
- Reverse transcriptase;** Delavirdine; HIV; Nevirapine; NNRTIs (non-nucleoside reverse transcriptase inhibitors); Triple-drug combinations **38**, 153
- Ribonucleotide reductase;** Herpes simplex virus; Acyclovir; Interferon; Synergy **38**, 107
- Rimantadine;** Anti-influenza compounds; Amantadine **38**, 213
- RSV;** Cotton rats; Antiviral; Pneumonia; Prophylaxis; Bronchiolitis **38**, 31
- RSV;** Fluoroalkylated oligomer; HIV-1; HSV-1; HSV-2; Viral adsorption inhibitor **38**, 141
- Semliki Forest virus;** Virus inactivation; Singlet oxygen; Vesicular stomatitis virus **38**, 55
- Simian rotavirus SA11;** Heterologous G3-VP7; Homotypic single-VP7 **38**, 15
- Singlet oxygen;** Virus inactivation; Semliki Forest virus; Vesicular stomatitis virus **38**, 55
- Structure;** Antiviral activity; In vitro; In vivo; Poly(G)·poly(C); Polyribonucleotide duplexes; Template biosynthesis **38**, 131
- Summer flu;** Enteroviruses; Viral syndrome; Coxsackieviruses; Aseptic meningitis **38**, 1
- Synergy;** Herpes simplex virus; Acyclovir; Interferon; Ribonucleotide reductase **38**, 107
- Synergy;** Interferon; Herpes simplex virus; Acyclovir **38**, 95
- Template biosynthesis;** Antiviral activity; In vitro; In vivo; Poly(G)·poly(C); Polyribonucleotide duplexes; Structure **38**, 131
- T helper type 1;** Interleukin 12; Influenza A virus infection; Cytokine production **38**, 117
- Topical;** Herpes; Immune cells; Virus; Foscarnet; Antiviral **38**, 43
- Triple-drug combinations;** Delavirdine; HIV; Nevirapine; NNRTIs (non-nucleoside reverse transcriptase inhibitors); Reverse transcriptase **38**, 153
- Vesicular stomatitis virus;** Virus inactivation; Singlet oxygen; Semliki Forest virus **38**, 55
- Viral adsorption inhibitor;** Fluoroalkylated oligomer; HIV-1; HSV-1; HSV-2; RSV **38**, 141
- Viral burden;** Cartesian coordinate analysis; CD4+ cell; HIV-1 RNA; Virulence; Virologic response modifiers; Pathogenesis; Clinical trials **38**, 181
- Viral syndrome;** Enteroviruses; Summer flu; Coxsackieviruses; Aseptic meningitis **38**, 1
- Virologic response modifiers;** Cartesian coordinate analysis; CD4+ cell; HIV-1 RNA; Viral burden; Virulence; Pathogenesis; Clinical trials **38**, 181
- Virulence;** Cartesian coordinate analysis; CD4+ cell; HIV-1 RNA; Viral burden; Virologic response modifiers; Pathogenesis; Clinical trials **38**, 181
- Virus;** Herpes; Immune cells; Topical; Foscarnet; Antiviral **38**, 43
- Virus inactivation;** Singlet oxygen; Semliki Forest virus; Vesicular stomatitis virus **38**, 55